ClinicalTrials.gg
CompletedNCT05176223Updated Sep 29, 2026Results posted

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

A Phase 2 interventional study of Computed Tomography and Gallium Ga 68 Gozetotide in Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 and Stage IV Hepatocellular Carcinoma AJCC v8, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Carcinoma, Hepatocellular by Mayo Clinic — 6 open to participants now, 7 under way, none of them phase 3. Carcinoma, Hepatocellular · Mayo Clinic.

Enrollment
8th of 13
26 · median 27
Started
2022
with 2 others
Phase 2
6 of 21
2 open now
Registered
17th of 21
by date

Among the 21 studies in Carcinoma, Hepatocellular by Mayo Clinic, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 in phase 2, and was the 17th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

6 of the 21 studies in Carcinoma, Hepatocellular by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Hepatocellular by Mayo Clinic, or all of them as a file.
02

Study summary

This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.

Read the detailed description

PRIMARY OBJECTIVES:

I. To test the performance of novel biomarkers derived from PSMA PET/computed tomography (CT) to measure response compared to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, in advanced hepatocellular carcinoma (HCC) patients treated with immunotherapy.

II. To identify precision imaging biomarkers that can predict response of HCC to novel immunotherapy.

OUTLINE:

Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed-up every 6 months for 3 years.

03

Conditions studied

  • Advanced Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Unresectable Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with confirmed HCC not amenable to curative resection, transplantation or ablative therapies
  • Have radiographically by
  • Eligible for atezolizumab/bevacizumab front line therapy
  • Male or female with age greater than 18 years, with the capacity and willingness to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan
  • Patients with higher than the weight/size limitations of PET/CT scanner
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment (68GA PSMA PET/CT)

    Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.

    Procedure: Computed Tomography · Drug: Gallium Ga 68 Gozetotide · Procedure: Positron Emission Tomography

Interventions

  • ProcedureComputed Tomography

    Undergo 68Ga PSMA PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography

  • DrugGallium 68 PSMA-11Studies of Gallium 68 PSMA-11Gallium 68 PSMA-11 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Undergo 68Ga PSMA PET/CT

    Also known as: (68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC, (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC, (68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC, (68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC, (68Ga)Glu-urea-Lys(Ahx)-HBED-CC, 68Ga-DKFZ-PSMA-11, 68Ga-HBED-CC-PSMA, 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC, 68Ga-PSMA, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC, [68Ga] Prostate-specific Membrane Antigen 11, [68Ga]GaPSMA-11, Ga PSMA, Ga-68 labeled DKFZ-PSMA-11, Ga-68 labeled PSMA-11, GA-68 PSMA-11, Gallium Ga 68 PSMA-11, Gallium Ga 68-labeled PSMA-11, GALLIUM GA-68 GOZETOTIDE, Gallium-68 PSMA, Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC, GaPSMA, PSMA-HBED-CC GA-68

  • ProcedurePositron Emission Tomography

    Undergo 68Ga PSMA PET/CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT

06

What researchers measure

Primary outcomes

  1. Time to Treatment Response

    Defined as the time from study registration to complete response/partial response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and per PSMA positron emission tomography (PET)/computed tomography (CT).

    Time frame: 36 weeks

  2. Proportion of Progression Free Survival (PFS) at 6 Months

    Defined as the length of time during and after treatment that a patient lives with cancer without the disease worsening, per RECIST and PSMA PET/CT

    Time frame: 6 months

  3. Time to Progression

    Defined as the time from study registration to disease progression per RECIST 1.1 and PSMA PET/CT.

    Time frame: 32 months

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (68GA PSMA PET/CT)
Started26
Completed24
Not completed2
Withdrew: Ineligible1
Withdrew: Non-psma avid patient1

Outcome measures

PrimaryTime to Treatment Response

Defined as the time from study registration to complete response/partial response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and per PSMA positron emission tomography (PET)/computed tomography (CT).

Time frame:
36 weeks
Reported as:
Median · weeks
Time to Treatment Response
weeksTreatment (68GA PSMA PET/CT)
Time to Treatment Response18.0 (13.3 to NA)
PrimaryProportion of Progression Free Survival (PFS) at 6 Months

Defined as the length of time during and after treatment that a patient lives with cancer without the disease worsening, per RECIST and PSMA PET/CT

Time frame:
6 months
Reported as:
Number · proportion of participants w/out event
Proportion of Progression Free Survival (PFS) at 6 Months
proportion of participants w/out eventTreatment (68GA PSMA PET/CT)
Proportion of Progression Free Survival (PFS) at 6 Months0.66 (0.49 to 0.88)
PrimaryTime to Progression

Defined as the time from study registration to disease progression per RECIST 1.1 and PSMA PET/CT.

Time frame:
32 months
Reported as:
Median · months
Time to Progression
monthsTreatment (68GA PSMA PET/CT)
Time to ProgressionNA (11.5 to NA)

Adverse events

Collected over 32 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (68GA PSMA PET/CT)13/24 (54.2%)0/24 (0%)9/24 (37.5%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTreatment (68GA PSMA PET/CT)
VomitingGastrointestinal disorders2/24
FallInjury, poisoning and procedural complications2/24
DyspneaRespiratory, thoracic and mediastinal disorders2/24
Abdominal painGastrointestinal disorders2/24
HypoxiaRespiratory, thoracic and mediastinal disorders1/24
HeadacheNervous system disorders1/24
HyponatremiaMetabolism and nutrition disorders1/24
Generalized muscle weaknessMusculoskeletal and connective tissue disorders1/24
HyperkalemiaMetabolism and nutrition disorders1/24
Pain in extremityMusculoskeletal and connective tissue disorders1/24

Baseline characteristics

All eligible, PSMA avid patients included in analysis

Age, Continuous
Age, Continuous(years)Treatment (68GA PSMA PET/CT)
Mean67.8 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (68GA PSMA PET/CT)
Female6
Male18
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (68GA PSMA PET/CT)
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White21
More than one race0
Unknown or Not Reported0
BMI
BMI(kg/m^2)Treatment (68GA PSMA PET/CT)
Mean29.5 ± 5.28
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Dec 2025, 47 months.

Results were first posted in Sep 2026, 8 months after primary completion.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's 47 months is close to that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2021
First posted
Jan 4, 2022
StartActual
Jan 30, 2022
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Enrollment
29→26
Sep 29, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • EditedTime to treatment responseTreatment ResponseTime frame: Up to 12 cycles of treatment or 36 weeks → 36 weeks
  • EditedProportion of Progression free survivalFree Survival (PFS) at 6 monthsMonthsTime frame: At 6 months → 6 months
  • EditedTime to progressionProgressionTime frame: Up to 3 years → 32 months
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Enrollment 29→26
    Primary outcomes 3 edited
    What changed in the outcomes
    • EditedTime to treatment responseTreatment ResponseTime frame: Up to 12 cycles of treatment or 36 weeks → 36 weeks
    • EditedProportion of Progression free survivalFree Survival (PFS) at 6 monthsMonthsTime frame: At 6 months → 6 months
    • EditedTime to progressionProgressionTime frame: Up to 3 years → 32 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05176223
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Jan 4, 2022
Start date
Jan 30, 2022
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Nguyen H. Tran, MD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium 68 PSMA-11

Start the discussion